LINSEY ITTYIPE, FNP-C
Family Nurse Practitioner · BELLAIRE, TX
Individual Active NPI 1558993733
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 577 | 221,689 | $17,595,047 | $4,693,123 | $3,735,032 |
| 2023 | 506 | 127,954 | $14,039,336 | $4,411,325 | $3,504,743 |
| 2022 | 570 | 141,883 | $16,241,464 | $4,693,030 | $3,734,657 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J0174 | Injection, lecanemab-irmb, 1 mg | 67,200 | $1 | $1 |
| J3111 | Injection, romosozumab-aqqg, 1 mg | 44,520 | $11 | $8 |
| J0897 | Injection, denosumab, 1 mg | 12,900 | $25 | $20 |
| J1756 | Injection, iron sucrose, 1 mg | 4,800 | $0 | $0 |
| J3245 | Injection, tildrakizumab, 1 mg | 4,300 | $135 | $107 |
| J2182 | Injection, mepolizumab, 1 mg | 4,000 | $30 | $24 |
| J2357 | Injection, omalizumab, 5 mg | 3,450 | $38 | $30 |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 1,820 | $31 | $25 |
| J0517 | Injection, benralizumab, 1 mg | 1,290 | $165 | $131 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 1,232 | $0 | $0 |
| 96372 | Injection of drug or substance under skin or into muscle | 862 | $12 | $9 |
| J3489 | Injection, zoledronic acid, 1 mg | 385 | $7 | $4 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Family Nurse Practitioner | 363LF0000X | ✓ | AP144557 | TX |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- No
Other Family Nurse Practitioner providers in Texas
- NPI 1629472873
- NPI 1073094165
- NPI 1407295058
- NPI 1073154209
- NPI 1720441561
- NPI 1154387702
- NPI 1629838958
- NPI 1801292313
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.